Pelvic Congestion Syndrome Treatment: Market Insights
Pelvic congestion syndrome is a condition that causes pain in the pelvic region. This pain occurs mostly due to problems in the veins near the pelvic area. Pelvic congestion syndrome is a common gynecological condition in women that leads to often severe chronic pelvic pain. The causes of pelvic congestion syndrome generally involves pelvic inflammatory disease, endometriosis, pelvic varicosities and other conditions. Mostly in hospitals, pelvic congestion syndrome diagnosis is generally performed by venography. Prior to venogram, a pelvic ultrasound or other imaging study is performed to check any abnormalities.
According to a study reported in 2016, it is estimated that 10 million women suffer from pelvic congestion syndrome with approximately 7 million women avoid seeking treatment. Worldwide prevalence of chronic pelvic pain is estimated to vary from 26.6% in Egypt and 5.7% in Austria. The economic scenario of the pelvic congestion syndrome has a great impact.
The annual medical cost of pelvic congestion syndrome diagnosis and pelvic congestion syndrome treatment is estimated to be around US$ 1.2 billion and the cost of lost productivity in patients with pelvic congestion syndrome treatment is estimated to be around US$ 15 billion annually.
Pelvic Congestion Syndrome Treatment: Market Dynamics
Pelvic congestion syndrome is a common issue among women between the 20 and 50 years of age. Mostly doctors prescribed painkillers for pelvic congestion syndrome treatment to reduce the pain. Apart from this hormonal therapy is also given to reduce the congestion in pelvic congestion syndrome treatment. Various treatment procedures in pelvic congestion syndrome treatment expected to drive the market. Hormonal treatment helps to reduce congestion and blood flow of the viscous vein.
If these pelvic congestion syndrome treatment fails, minimally invasive therapies such as nonsurgical embolization are mostly used in pelvic congestion syndrome treatment. Advancement in latest technologies and procedures is likely anticipate to boost the pelvic congestion syndrome treatment market. Lack of skilled professional and lack of awareness among people may restrain the growth of pelvic congestion syndrome treatment market. Cost of embolization procedures is also another factor that may hinder the pelvic congestion syndrome treatment market.
Know More Details About the Report
Pelvic Congestion Syndrome Treatment Market: Overview
Pelvic congestion syndrome treatment market is expected to have gradual growth. Medical pelvic congestion syndrome treatment includes danazol, psychotherapy, progestin, phlebotonics, gonadotropins receptor agonists (GnRH) which is done by hormone replacement therapy, nonsteroidal anti-inflammatory drugs, and dihydroergotamine. Also some of the latest technologies which consists of transcatheter embolotherapy is being currently used in pelvic congestion syndrome treatment. Medical therapy has shown to provide relief to the patients but the outcome is for a shorter period.
However, Gonadotrophin releasing hormone agonist called goserelin has shown satisfactory results in pelvic congestion syndrome treatment pain. Apart from this, hysterectomy with oophorectomy has proven to provide moderate relief to patients with pelvic congestion syndrome treatment. Embolotherapy has been an exciting therapy in pelvic congestion syndrome treatment. With advances in medical sciences, pelvic congestion syndrome treatment market expected to have significant growth in next few years.
Pelvic Congestion Syndrome Treatment Market: Region-wise Outlook
On the basis of geography, the global pelvic congestion syndrome treatment market is segmented into seven key regions: North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan, Japan and Middle East & Africa. North America is expected to dominate the global pelvic congestion syndrome treatment market due to advancement in technology, high healthcare facilities and improve infrastructure which will facilitate the growth of pelvic congestion syndrome treatment market.
Europe is also likely anticipate to boost the overall growth of pelvic congestion syndrome treatment market owing to adoption of new treatment options and availability of drugs and increase in procedures of injectable used for the pelvic congestion syndrome treatment.
Asia Pacific is expected to have the potential to drive the global pelvic congestion syndrome treatment market due to increase in prevalence of pelvic congestion syndrome. According to one report, the prevalence rate of chronic pelvic pain in developing countries accounts to 5.2% in India and 43.2% in Thailand. Among these cases, pelvic congestion syndrome reports 16% to 31% of all cases which is likely to have a considerable growth in pelvic congestion syndrome treatment market.
Middle East and Africa has less potential to drive the pelvic congestion syndrome treatment market due to lack of awareness among people and poor healthcare facilities may restrain the growth of the pelvic congestion syndrome treatment market.
Avail customized purchase options for your needs
Pelvic Congestion Syndrome Treatment Market: Key Players
Some of the key players present across the value chain of the global pelvic congestion syndrome treatment market are Sanofi, TOLMAR Inc., Actiza Pharmaceuticals, Pfizer, Debio RP, AbbVie Inc, AstraZeneca, Novartis Pharmaceuticals Corporation, Indivior Inc., Pernix Ireland Pain Limited, ALZA Corporation, Fresenius Kabi USA,LLC
The report covers exhaustive analysis on:
- Market Segments
- Market Dynamics
- Market Size
- Current Trends/Issues/Challenges
- Competition & Companies involved
- Value Chain
An Adaptive Approach to Modern-day Research Needs
The regional analysis includes:
- North America (U.S., Canada)
- Latin America (Mexico. Brazil)
- Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)
- Eastern Europe (Poland, Russia)
- Asia-Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)
- The Middle East and Africa (GCC, S. Africa, N. Africa)
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
- Detailed overview of parent market
- Changing market dynamics in the industry
- In-depth market segmentation
- Historical, current and projected market size in terms of volume and value
- Recent industry trends and developments
- Competitive landscape
- Strategies of key players and products offered
- Potential and niche segments, geographical regions exhibiting promising growth
- A neutral perspective on market performance
Have a report related query? Speak to us directly
Pelvic Congestion Syndrome Treatment Market: Segmentation
The global pelvic congestion syndrome treatment market is segmented by disease type, medication and distributional channel.
- Segmentation by Disease Type
- Primary Pelvic Congestion Syndrome Treatment
- Secondary Pelvic Congestion Syndrome Treatment
- Segmentation by Medication
- NSAIDs (nonsteroidal anti-inflammatory drugs) Pelvic Congestion Syndrome Treatment
- Psychotherapy Pelvic Congestion Syndrome Treatment
- Analgesics Pelvic Congestion Syndrome Treatment
- Segmentation by Distributional Channel
- Diagnostics laboratories
- Gynecology Clinics
- Ambulatory Surgical Centers
Need an Exclusive Report for your Unique Requirement?
- Our Clients -
- Evaluate How Fact.MR's Report Can Help. -
Is the market research conducted by Fact.MR?
Yes, the report has been compiled by expert analysts of Fact.MR, through a combination of primary and secondary research. To know more about how the research was conducted, you can speak to a research analyst.
What research methodology is followed by Fact.MR?
Fact.MR follows a methodology that encompasses the demand-side assessment of the market, and triangulates the same through a supply-side analysis. This methodology is based on the use of standard market structure, methods, and definitions.
What are the sources of secondary research?
Fact.MR conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request.
Who are the respondents for primary research?
Fact.MR speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, and industry experts. For a full list of primary respondents, please reach out to us.
Is a sample of this report available for evaluation?
Yes, you can request a sample, and it will be sent to you through an email.